M. Smith

发表

Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report.

S. Donaldson, R. Heyn, T. Vietti, 1994, Medical and pediatric oncology.

Phase II window studies: 10 years of experience and counting.

M. Smith, B. Anderson, 2001, Journal of pediatric hematology/oncology.

National cancer clinical trials: children have equal access; adolescents do not.

A. Bleyer, B. Pollock, L. Robison, 1997, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Trends in reported incidence of primary malignant brain tumors in children in the United States.

B. Freidlin, L. Ries, R. Simon, 1998, Journal of the National Cancer Institute.

Investigation of leukemia cells from children with common acute lymphoblastic leukemia for genomic sequences of the primate polyomaviruses JC virus, BK virus, and simian virus 40.

K. Shah, G. Reaman, H. Strickler, 1999, Medical and pediatric oncology.

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.

R. Simon, E. Korn, L. Rubinstein, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conduct of phase I trials in children with cancer.

G. Vassal, M. Bernstein, G. Reaman, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bivalirudin for the treatment of patients with confirmed or suspected heparin‐induced thrombocytopenia

J. Bartholomew, M. Militello, H. Gornik, 2014, Journal of thrombosis and haemostasis : JTH.

Potential for immunotherapy: PEM as a target antigen

N. Peat, J. Taylor‐Papadimitriou, J. Burchell, 1995 .

Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins.

E. Gehan, L. Rubinstein, R. Heyn, 1993, Journal of the National Cancer Institute.

Where to next with retinoids for cancer therapy?

M. Smith, B. Anderson, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer.

P. Adamson, R. Murphy, F. Balis, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retinoid Therapy for Acute Promyelocytic Leukemia: A Coming of Age for the Differentiation Therapy of Malignancy

D. Parkinson, M. Smith, Malcolm A. Smith, 1992, Annals of Internal Medicine.

Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma.

R. Simon, R. Ungerleider, M. Horowitz, 1991, Journal of the National Cancer Institute.

Modifying risks of secondary leukemias: is drug scheduling important?

J. Karp, M. Smith, 1996, Journal of the National Cancer Institute.

CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA)

M. Neary, W. Oh, M. Nakabayashi, 2005 .

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.

E F Heineman, J L Warren, L. Ries, 1999, Journal of the National Cancer Institute.

Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States.

L. Ries, R. Tarone, S. Devesa, 1999, Journal of the National Cancer Institute.

Retinoids in cancer therapy.

B. Cheson, D. Parkinson, M. Friedman, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant therapy in cancer treatment

E. Trimble, C. Carter, R. Ungerleider, 1993, Cancer.

Trans-retinoic acid and related differentiation agents.

D. Parkinson, M. Friedman, H. Stevenson, 1992, Seminars in oncology.

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

C. Pui, R. Gelber, E. Korn, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The secondary leukemias: challenges and research directions.

J. Karp, M. Smith, R. McCaffrey, 1996, Journal of the National Cancer Institute.

A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program

P. Houghton, R. Lock, H. Carol, 2016, Leukemia.

L. Rubinstein, R. Ungerleider, M. Smith, 1994, Medical and Pediatric Oncology.

The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention.

J. Karp, M. Smith, 1997, Seminars in oncology.

Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.

B. Freidlin, P. Catalano, L. Rubinstein, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uniform criteria for childhood acute lymphoblastic leukemia risk classification.

A. Bleyer, S. Sallan, W. Crist, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age-specific incidence of acute lymphoblastic leukemia in U.S. children: in utero initiation model.

R. Simon, T. Chen, M. Smith, 1997, Journal of the National Cancer Institute.

The impact of doxorubicin dose intensity on survival of patients with Ewing's sarcoma.

M. Smith, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age effects of radiation-associated neurotoxicity in children.

R. Simon, M. Smith, 1993, Journal of Clinical Oncology.

Dose-dependent pharmacokinetics of all-trans-retinoic acid.

P. Adamson, R. Murphy, F. Balis, 1992, Journal of the National Cancer Institute.